New Search

If you are not happy with the results below please do another search

34 search results for: amed

2

Amedisys: Caught Between a RAC and a Hard Place

Citron first reported on Amedisys over a year ago.  Never before have we received as much correspondence from former employees as we did after this story.  Last month, the market witnessed the abrupt resignations of two key executives from Amedisys.  In this post, Citron will shed some light on the “story behind the story” of […]

3

Seeking Healthy Returns in Amedisys? (NASDAQ:AMED)

Better get a Second Opinion…. Citron Research was first drawn to research Arthrocare because one division was running margins that wildly outperformed all their competitors.  After working countless hours with private investigators and reviewing hundreds of documents, we were able to draw a line to what we believe explained the extreme outperformance:  fraud on the […]

4

Citron Updates Peloton

Peloton Investors Must “Eat the Apple” and Accept the Truth 2020 Target Price – $5 While Citron Research is widely known as a “short selling” research firm, we must first say that we are deeply concerned about the turn of events in this country and would never use this platform to spread fear or undue […]